Why Attend
The Onco Cell Therapy Summit (OCTS), November 16 - 18, Boston USA, brings the industry together to share novel research, manufacturing techniques, and regulatory best practice. Each session of OCTS 2021 is dedicated to the process of translating R&D into commercially viable oncological therapies.
The race for bringing the first BCMA targeting CAR-T to the market is reaching a climax and next-generation cell therapies are at the front of mind for those in both industry and research.
Significant break throughs in GvHD for allogeneic treatments and in the use of alternative cell therapies mean that onco cell therapies are embedding themselves as the 5th pillar of oncology. New combination studies and manufacturing capabilities are showing even more promise for this sector, but with current treatments still having high costs of use and as there are limited patient pools, there are still challenges in both clinical and commercial use of these therapies.
We’ve worked with industry partners to ensure that OCTS 2021 is dedicated to the effective translation and commercialization of research into safe and efficacious therapies and address these challenges.
WHO WILL BE THERE
Network with industry experts from:
- Big pharma and biotech
- Cell Therapy Academics and clinicians
- Process standardisation - technology/services
- Logistics companies - cell storage/transport
- Service providers - CRO’s, Consultants, Government
This years confirmed attendees include:
Meet our 2021 Industry- Leading Speakers
Frank Fan
Simon Bornschein
Paul Lammers
James Trager
Robert Tighe
Gary Lee
John Rossi
Adrian Bot
Steven Kanner
Donna Rill
Emilie Gauthy
Knut Niss
Dr. Niss has served as Chief Technology Officer since March 2018. Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He also served as Senior R&D Program Manager at EMD Millipore, where he established processes for the large-scale expansion of adult and pluripotent stem cells. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. He holds a Ph.D. in molecular biology from Humboldt University of Berlin, and an M.S. in microbiology from the University of Göttingen in Germany. Dr. Niss completed his postdoctoral research at Boston Children’s Hospital and the Dana-Farber Cancer Institute.
John Tomtishen
Anthony Colenberg
Tatiana Novobrantseva
Kipp Weiskopf
Yaron Pereg
David Cheresh
Michael Klichinsky
Ashish Kulkarni
Sandro Matosevic
Eric Von Hofe
Charles Mooney
Albert Ribickas
Daniel Getts
Lawrence Lamb
Moa Fransson
Rafael Amado
Sheng Lin-Gibson
William Shingler
Charles Morris
Melissa Sebok
Tuval Ben-Yehezkel, PhD
Tuval Ben-Yehezkel is a scientist-entrepreneur focused on applied genomics and synthetic biology. Authored key patents, publications and book chapters in synthetic biology and genomics. Founded and secured $15.3M in funding for two biotech start-up companies.
David Cheresh
Adrienne Farid
Eric Gehrie
Daniel Getts
Vineet Kacker
Alina Lelic
Hy Levitsky
Dongfang Liu
Sandro Matosevic
Nina Möker
Charles Morris
Nicolas Poirier
Christine Probst
Martha Salinas
Alaina Schlinker
Jay Tong
Agenda
Find out who is speaking at the 5th annual Onco Cell Therapy Summit.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
Join 500+ attendees, including speakers:
- Paul Rennert, Aleta who will discuss enhanced approaches for cell therapies to address persistence, antigen loss and heterogeneity to overcome solid tumor targeting challenges
- Robert Hofmeister, CSO, TCR2 who is presenting on how to improve the persistence of T cells in targeting solid tumors by utilizing utilize TRuCs with IL-15 based enhancements
- CALIBR who will present research on establishing switchable CAR-T approaches in the treatment of r/r B cell malignancies to overcome key safety technologies that will prevent the life threatening side effects of some cell therapies
- Michael Klichinsky, VP Discovery & Co-Founder of Carisma Therapeutics will give the first in-person data presentation on CAR macrophages
- Adrienne Farid, Chief Operating Officer of Century Therapeutics, who will break down the rationale for iPSC derived cell therapies and the considerations for safety and process
- John Tomtishen, Director of Manufacturing – Technical Operations, Legend Biotech will discuss the future of automation of the vein-to-vein process in cell therapies
Download 2021 Agenda
Sponsors
Headline Partner
Miltenyi Biotec
Website: www.miltenyibiotec.com
At Miltenyi Biotec, we are committed to enabling the delivery of new cell and gene therapy (CGT) treatment options to patients with unmet medical needs. We develop tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacturing of complex CGT products. In addition, we offer contract development and GMP manufacturing of CGT products as well as design, development, and production of tailored GMP lentiviral vectors
Platinum Partner
Gold Partner
American Red Cross
Website: RedCrossBlood.org/cellulartherapy
The Cell & Gene Therapy Solutions division of the American Red Cross is a nationwide leader in the provision of allogeneic and autologous collections for cell and gene therapy. Our products support a broad range of uses, from bench research to use in clinical trials and the manufacture of commercial therapies.
We currently perform autologous Mononuclear Cell collections at 62 Red Cross sites across the country and at multiple hospital locations. Our allogeneic Mononuclear Cell products are collected from healthy donors at five Red Cross sites across the country, and can be shipped fresh or frozen.
Our five full-service cellular therapy labs perform processing, freezing and storage of apheresis material. This, along with our ability to offer robust customization, allows us to both collect and process apheresis products according to our customers’ specifications and unique needs.
Lonza
Website: www.lonza.com
At Lonza, we provide contract development, clinical and commercial manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges
We also bring exceptional service capabilities, global regulatory expertise, and expert technical service to support our customers in quickly delivering differentiated nutritional products to market.
nanoString
Website: https://www.nanostring.com/
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research and cited in 1,000+ peer review publications, has also now been applied to diagnostic use with the nCounter Dx Analysis System. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. Gene expression panels for immune- oncology, autoimmunity, CAR-T and other applications are ready off the shelf tools offered to the Nanostring customers.
ScaleReady
Website: www.scaleready.com
About Us
ScaleReady is a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf. Bringing together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing, ScaleReady provides leading therapeutic developers with the most simple, scalable, and versatile manufacturing platform in the industry. Our platform includes G-Rex® cell culture technology, the Lovo and Cue cell processing systems, and a wide range of GMP proteins, reagents, media, and gene editing technologies.
Blood Centers of America
Website: http://bca.coop/
BCA is the nation’s largest blood supply network, providing over 50 percent of the nation’s blood supply. This national organization is comprised of over 60 independent community blood centers with a deep local commitment to the communities and patients they serve.
The BCA network encompasses over 500 collection and testing sites across the United States. In addition to meeting the transfusion needs of the communities they serve, BCA members provide human blood products, custom collections, cell processing, testing, storage, distribution and other services to the therapeutic, diagnostic and cell therapy industries. BCA members actively collect and provide critical raw materials for manufacturing of autologous and allogeneic cell-based therapies. Collectively BCA’s members interact with nearly three million individual blood donors annually.
In response to the COVID-19 pandemic, BCA optimized the collection of convalescent plasma donations from those recovered from COVID-19 (CCP). The donated blood is processed, and the plasma and antibodies are delivered intravenously to people actively battling the COVID-19 virus. BCA’s effort with CCP has been as a partner of Operation Warp Speed, which includes involvement with HHS, CDC, NIH, BARDA, DOD and other public agencies for the development of COVID-19 vaccine and therapeutic treatments.
APCER Life Sciences
Website: https://www.apcerls.com/
Together for Patient Safety
Patient safety has been and will always be the utmost priority for achieving high quality healthcare.
APCER Life Sciences is committed to provide assurance services to the pharmaceutical and biotech companies who are dedicated towards developing drugs, vaccines and advanced therapies for diseases and betterment of the society.
The ongoing public health crisis and life-threatening ailments like rare diseases require safer and effective therapies based on the benefit risk assessment. Our clients benefit from the medical and scientific knowledge which our team of experts bring forth by continuously monitoring scientific and regulatory developments globally thereby ensuring ‘Patient Safety’ with high quality treatments. Brexit has brought about changes in pharmacovigilance requirements for products authorized in the United Kingdom and Europe. We help provide consulting to the biopharma companies who want to market their products and face difficulties in getting market approvals in these regions. Our team of experts work together in mapping out cohesive solutions to help in smooth transitioning of processes.
About APCER Life Sciences
APCER Life Sciences provides comprehensive drug safety/pharmacovigilance, medical information, medical writing, regulatory services, quality assurance and risk management programs to pharmaceutical and biotech companies globally.
We bring medicinal / scientific expertise through our healthcare professionals & physicians and address end-end pharmacovigilance requirements for North America, UK & Europe markets. Our clients benefit from our vast experience in regulatory submissions across 100+ countries and consultative approach towards audit /inspection readiness.
Our focus towards Patient safety and Risk profile management makes us the preferred choice for pharma companies who are looking for pre /post marketing compliance & reporting solutions.
KBI Biopharma
Website: https://www.kbibiopharma.com/
KBI Biopharma, Inc. is a biopharmaceutical Contract Development and Manufacturing Organization that accelerates the development of innovative discoveries into life-changing biological products. From early-stage to academic/non-profit organizations, to many of the world’s largest pharmaceutical companies, KBI has served 250+ clients globally to accelerate and optimize their drug development programs.
KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical characterization techniques toward the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapy products for our clients. KBI was founded in 1996 and operates 3 manufacturing facilities: Durham (NC), Boulder (CO), and The Woodlands (TX).
Terumo BCT
Website: https://www.terumobct.com/cell-therapy-technologies
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, believes in the potential of blood and cells to do even more for patients than they do today. Terumo BCT’s Cell Therapy Technologies business enables researchers, developers and manufacturers to create next-generation cell and gene therapies.
Event Partner
Berkley Lights
Website: https://www.berkeleylights.com/
OUR MISSION
We find the best cells.
Discovery of cellular therapies, biopharmaceuticals, and other cell-based products depends on precise, time-consuming, cell-by-cell manipulations. But biologists need to move faster and more efficiently to meet today’s scientific demands. Our mission is to accelerate the use of cell-based products by providing researchers access to the Berkeley Lights Platform to find the best cells in a fraction of the time and at a fraction of the cost of traditional methods.
Miltenyi Biotec
Website: https://www.miltenyibiotec.com/GB-en/
Please visit our website for more information.PeproTech
Website: www.peprotech.com
P=eproTech creates the building blocks of your life science research by manufacturing high-quality products that advance scientific discovery and human health. Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines
Sexton Biotechnologies
Website: www.sextonbio.com
Sexton Biotechnologies is a company focused on the development and sales of bioproduction tools for cell and gene therapy founded in 2019, located in Indianapolis, IN. Sexton develops purpose-built CGT tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points, and labor costs. Sexton's portfolio includes the CellSeal platform of cryo-storage tools and fill/finish systems and human platelet lysate growth supplements.
Biocytogen
Website: https://biocytogen.com/
Biocytogen offers a full suite of integrated services to advance therapeutic discovery and development for customers in the biotech and pharmaceutical industries, using state-of-the-art technologies for single cell antibody discovery, gene editing, and a large supply of animal disease models. Biocytogen’s in vivo pharmacology services support efficacy testing of antibody therapeutics, small molecules, and CAR-T therapy, using custom humanized mice expressing knocked-in human targets, wild-type mice, or severely immunodeficient (B-NDG) mice. Biocytogen collaborates with global partners to accelerate the discovery and development of novel therapeutics for oncology, immuno-oncology, autoimmune diseases, and other inflammatory diseases.
For more information, please visit www.biocytogen.com.
CTI
Website: https://www.ctifacts.com/
From a small team in an old carriage house to associates in more than 60 countries across the world.
We have now worked on more than 6000 projects, worked on every continent except Antarctica, and have contributed to more than 130 new drug and device approvals through global regulatory agencies such as the FDA, EMA, and others. Currently, we work with more than 200 pharmaceutical and emerging biotechnology and medical device companies.
Loop Genomics
Website: www.loopgenomics.com
Loop Genomics develops and commercializes Loopseq, a technology for accurate long-read DNA sequencing. Loopseq is a sample prep and software combination that transforms all Illumina sequencers into high-throughput, long-read, highly accurate single-molecule counting sequencing machines. The technology is a general purpose, providing accurate long-read sequencing solutions across a diverse repertoire of sequencing applications.
In the protein engineering space, LoopSeq enables, for the first time, accurate long-read characterization of complex variant libraries and high-throughput long-read clonal sequencing using Illumina sequencers. It's unique barcoding technology removes PCR bias, produces highly accurate long-reads and removes critical bottlenecks in the protein engineering workflow.
Jellagen
Website: http://www.jellagen.co.uk/
Jellagen Ltd is a marine biotechnology company manufacturing next generation Collagen Type 0 for medical and scientific research applications. Our strategic mission is to commercialize marine sourced Collagen Type 0 based upon its many advantages over mammalian sources, while also exploring new therapeutic opportunities which arise from the unique qualities of Collagen Type 0 as a biomaterial. The Jellagen business model is based upon our deep belief in building sustainable sources for critical biomaterials which do not carry the environmental and human health risks of traditional collagen sources. Our research and development strategy focuses on establishing partnerships with medical institutions of the highest reputation to investigate the use of Collagen Type 0 as a treatment for skin diseases and as a biomaterial for tissue reconstruction.
Founded in Cardiff, Wales in 2015, Jellagen is already marketing a range of next generation Collagen Type 0 products for research use, while also developing clinical grade formulations for therapeutic and medical device applications. Based on the pioneering research of Professor Andrew Mearns Spragg, collagen in Jellagen’s products is extracted from Rhizostoma pulmo, an ancient species of large jellyfish common to the Irish Sea. Peer-reviewed published research as well as the company’s own application specific advisory papers demonstrate the significant advantages of Collagen Type 0 over mammalian collagen for both research and medical uses.
Gates Biomanufacturing Facility
Website: http://gatesbiomanufacturing.com/
The Gates Biomanufacturing Facility at the University of Colorado Anschutz Medical Campus is a 14,000 square ft. GMP compliant manufacturing facility that provides cell-based therapies and protein biologics for use in preclinical investigations and Phase I and Phase II human clinical trials. The GBF was established in 2015 though partnership with the Gates Center for Regenerative Medicine, University of Colorado Health, Children’s Hospital of Colorado, University of Colorado-School of Medicine, and the Gates Frontiers Fund.
Our Mission is to accelerate the translation of scientific discoveries into human clinical trials as safely, efficiently, and cost effectively as possible according to high quality standards. We serve academic researchers, clinicians, early stage biotechnology companies and established pharmaceutical companies throughout the US.
In connection with our manufacturing, we provide the following services:
- Cell therapy and Protein product process development, consultation, and support
- Cell therapy and Protein product manufacturing, characterization, storage, and distribution
- Regulatory consultation and support
- Quality control
- Quality assurance managed through an electronic Quality Management System (QMS) with a dedicated staff of 16 people.
InVitria
Website: https://invitria.com/
InVitria’s portfolio of chemically defined blood-free products enables development and production of novel therapeutics without use of any blood-derived components.
Barrington James
Website: https://barringtonjames.com/
Barrington James are your global and award winning Life Science Recruitment experts. Having grown in both size and reputation since 2002, we now operate across three continents and are at the forefront of recruiting top talent for the most innovative Biotech, Pharmaceutical and Medical Device companies.
We have a specialist division solely dedicated to Cell & Gene which is headed up by our Senior Consultant Shannon Taylor whose sole focus is to provide clients with candidates to support the ongoing growths of their business. Which can differ from small start-up Biotechs, Consultancies to CDMOs as well as large pharma. Obtaining the specialist skills in the facilitating of candidates to match them to niche opportunities urgent appointment and key accounts.
We provide employees across vertical markets as this allows us to fully support your business goals and achievements. Whatever your recruitment needs are we are able to assist with our vast network and relationships across the globe .
Come to see us to discuss your next business or career move.
Media Partners
CheckRare
Website: https://checkrare.com/
CheckRare is a learning platform for health care professionals and patients. Our platform allows users to gain insight and learn about rare diseases, current and emerging therapies, clinical trials, and the BioPharma companies behind them. Our peer-to-peer content is a trusted source for education and industry-related content. Our native content and sponsored programs are developed through our website, e-newsletter, social media platforms, and live meetings. We are a trusted, strategic partner with all major organizations in the global network of rare disease advisors and advocates. There is no fee to register on CheckRare and all content is free of charge.
Gene Therapy Net
Website: www.genetherapynet.com
Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines.
World Pharma Today
Website: https://www.worldpharmatoday.com/
Please visit our website for more information.FierceBiotech
Website: www.fiercebiotech.com
Read the latest biotechnology articles on biotech industry leaders, emerging biotech companies, FDA decisions, VC deals, and other biotech industry news.
FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval—and all the seed funding, venture capital, licensing deals, IPOs and M&A that happen along the way.
We track tiny, virtual startups and the biggest of Big Pharma, highlighting the accomplishments and acknowledging the defeats that all of them experience on their way to market with a new therapy or device.
The FierceBiotech team transcends the daily as well, with comprehensive coverage of key medical meetings plus special reports that highlight up-and-comers and shed new light on industry heavyweights.
Pharma Journalist
Website: www.pharmajournalist.com
Pharma Journalist is a leading international B2B magazine providing the global information and the recent updates in the Pharmaceutical Industry.
Our editorial staff works dedicatedly to provide latest information of Pharmaceutical Industry in the form of articles, news, trends, analysis, market report, press releases, whitepapers, case studies, etc. which helps Industry professionals and decision makers to stay on the top of this fast-paced industry.
Various Online marketing services and promotional activities through Pharma Journalist helps companies and organizations to reach their target audience and create brand awareness.
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking. Contact Take a look at the Sponsorship Prospectus for more details, or discuss your objectives with Nathan Edwards, Head of Commercial Partnerships; [email protected].
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Sarah Rowlands, Marketing Director; sarah.rowlands[@]kisacoresearch.com.
Terms & Conditions
In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.
Returning Safely Measures
Whether sponsors, speakers or attendees, our customers attend Kisaco Research events to connect, learn and innovate to know more and do business. It is our commitment that as we return to in-person events, they can do this effectively, safely and with confidence.
All in-person Kisaco Research events will prioritize the health and safety of colleagues and customers and, in the first instance, will be run in accordance with official government and local authority guidance, as well as any venue or location-specific regulations.
Kisaco Research is committed to following the Association of Event Organisers All Secure Standard, which has been approved by by UK Government.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.